<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">detinf</journal-id><journal-title-group><journal-title xml:lang="ru">ДЕТСКИЕ ИНФЕКЦИИ</journal-title><trans-title-group xml:lang="en"><trans-title>CHILDREN INFECTIONS</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-8107</issn><issn pub-type="epub">2618-8139</issn><publisher><publisher-name>Association of Pediatricians and Infection Disease doctors</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22627/2072-8107-2021-20-2-49-56</article-id><article-id custom-type="elpub" pub-id-type="custom">detinf-599</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВОПРОСЫ ТЕРАПИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PROBLEMS OF THERAPY</subject></subj-group></article-categories><title-group><article-title>Совершенствование терапии генерализованных форм менингококковой инфекции у детей с помощью операций экстракорпоральной гемокоррекции</article-title><trans-title-group xml:lang="en"><trans-title>Improving the therapy of generalized forms of Meningococcal infection in children using extracorporeal hemocorrection</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8652-8997</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркова</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Markova</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маркова Ксения Витальевна - очный аспирант научно-исследовательского отдела нейроинфекций и органической патологии нервной системы.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>postgraduate student.</p><p>St. Petersburg</p></bio><email xlink:type="simple">ksenija-sidorova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8789-4750</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скрипченко</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Skripchenko</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скрипченко Елена Юрьевна - доктор медицинских наук, доцент, старший научный сотрудник научно-исследовательского отдела нейроинфекций и органической патологии нервной системы.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>MD, Associate Professor.</p><p>St. Petersburg</p></bio><email xlink:type="simple">wwave@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2213-0477</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Середняков</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Serednyakov</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Середняков Константин Владимирович - заведующий отделением анестезиологии и реанимации ФГБУ ДНКЦИБ ФМБА России.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Head of the Department of Anesthesiology and Reanimation.</p><p>St. Petersburg</p></bio><email xlink:type="simple">spbny@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6934-2223</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лобзин</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lobzin</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лобзин Юрий Владимирович - доктор медицинских наук, профессор, академик РАН, заслуженный деятель науки РФ, президент.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>MD, Professor, Аcademician.</p><p>St. Petersburg</p></bio><email xlink:type="simple">niidi@niidi.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8927-3176</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скрипченко</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Skripchenko</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Скрипченко Наталья Викторовна - доктор медицинских наук, Заслуженный деятель науки Российской Федерации, профессор, заместитель директора по научной работе ДНКЦИБ Федерального медико-биологического агентства; заведующая кафедрой инфекционных заболеваний у детей ФП и ДПО Санкт-Петербургский ГПМУ.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>MD, Professor.</p><p>St. Petersburg</p></bio><email xlink:type="simple">snv@niidi.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7972-1286</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карев</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karev</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карев Вадим Евгеньевич - доктор медицинских наук, руководитель научно-исследовательского отдела тканевых и патоморфологических методов исследования ФГБУ ДНКЦИБ ФМБА России.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>MD</p><p>St. Petersburg</p></bio><email xlink:type="simple">vadimkarev@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3185-516X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Усков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Uskov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Усков Александр Николаевич - доктор медицинских наук, профессор, директор ФГБУ ДНКЦИБ ФМБА.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>MD, Professor.</p><p>St. Petersburg</p></bio><email xlink:type="simple">aouskov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7965-7002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вильниц</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Vilnits</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вильниц Алла Ароновна - доктор медицинских наук, заведующий научно-исследовательским отделом терапии неотложных состояний ФГБУ ДНКЦИБ ФМБА; доцент кафедры инфекционных заболеваний у детей ФП и ДПО ФГБОУ ВО Санкт-Петербургский ГПМУ.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>MD</p><p>St. Petersburg</p></bio><email xlink:type="simple">vilnitz@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3130-1717</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горелик</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorelik</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Горелик Евгений Юрьевич - кандидат медицинских наук, старший научный сотрудник, исполняющий обязанности заведующего научно-исследовательским отделом нейроинфекций и органической патологии нервной системы ФГБУ ДНКЦИБ ФМБА.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>PhD, Senior Researcher.</p><p>St. Petersburg</p></bio><email xlink:type="simple">e.gorelik@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства<country>Россия</country></aff><aff xml:lang="en">Pediatric Research and Clinical Center for Infectious Diseases<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства; Санкт-Петербургский государственный педиатрический медицинский университет Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Pediatric Research and Clinical Center for Infectious Diseases; Saint Petersburg State Pediatric Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>08</day><month>07</month><year>2021</year></pub-date><volume>20</volume><issue>2</issue><fpage>49</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Маркова К.В., Скрипченко Е.Ю., Середняков К.В., Лобзин Ю.В., Скрипченко Н.В., Карев В.Е., Усков А.Н., Вильниц А.А., Горелик Е.Ю., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Маркова К.В., Скрипченко Е.Ю., Середняков К.В., Лобзин Ю.В., Скрипченко Н.В., Карев В.Е., Усков А.Н., Вильниц А.А., Горелик Е.Ю.</copyright-holder><copyright-holder xml:lang="en">Markova K.V., Skripchenko E.Y., Serednyakov K.V., Lobzin Y.V., Skripchenko N.V., Karev V.E., Uskov A.N., Vilnits A.A., Gorelik E.Y.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://detinf.elpub.ru/jour/article/view/599">https://detinf.elpub.ru/jour/article/view/599</self-uri><abstract><p>Генерализованные формы менингококковой инфекции (ГФМИ) являются значимой причиной смерти, достигающей при септическом шоке 80%. В ФГБУ ДНКЦИБ ФМБА России разработан алгоритм лечения детей с ГФМИ с рефрактерным септическим шоком и синдромом полиорганной недостаточности (СПОН), включающий в себя базисную медикаментозную терапию с проведением полимиксиновой гемоперфузии в комплексе с продленными методами экстракорпоральной гемокоррекции.</p><sec><title>Цель исследования</title><p>Цель исследования: оценить эффективность операций экстракорпоральной гемокоррекции у детей с ГФМИ с рефрактерным септическим шоком и СПОН.</p><p>Материалы и методы исследования: в отделение реанимации и интенсивной терапии ФГБУ ДНКЦИБ ФМБА России за анализируемый период 2006—2020 гг. было госпитализировано 34 ребенка с ГФМИ с рефрактерным септическим шоком и СПОН. Сформировано две группы: 1 группа — дети, госпитализированные в клинику ДНКЦИБ в период 2014—2020 гг. (п = 23), которым одновременно с продленными методами экстракорпоральной гемокоррекции проводилась полимиксиновая гемоперфузия, 2-я группа — дети, госпитализированные в период 2006—2013 гг. (п = 11), методы экстракорпоральной гемокоррекции не проводились. Для оценки результатов использовался U-критерий Манна — Уитни, дисперсионный анализ ANOVA.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение: применение операций экстракорпоральной гемокоррекции в комплексной терапии ГФМИ с рефрактерным септическим шоком и СПОН у детей обеспечивает стабилизацию центральной гемодинамики, уменьшает клинико-лабораторные воспалительные реакции, способствует снижению дозы вазопрессорных препаратов и параметров респираторной поддержки, а также увеличивает выживаемость пациентов на 82,6%.</p></sec></abstract><trans-abstract xml:lang="en"><p>Invasive meningococcal infection is a significant cause of death, reaching 80% in septic shock. The Pediatric Research and Clinical Center for Infectious Diseases (PRCCID) has developed an algorithm for the treatment of children with invasive meningococcal infection with refractory septic shock and multiple organ failure syndrome, which includes basic drug therapy with polymyxin hemoperfusion in combination with extended methods of extracorporeal hemocorrection.</p><sec><title>Purpose</title><p>Purpose: to evaluate the effectiveness of extracorporeal hemocorrection operations in children with invasive meningococcal infection with refractory septic shock and multiple organ failure syndrome.</p><p>Materials and research methods: to the intensive care unit of the PRCCID for the analyzed period 2006—2020 34 children were hospitalized with invasive meningococcal infection with refractory septic shock and multiple organ failure syndrome. Two groups were formed: Group 1 — children admitted to the PRCCID in the period 2014—2020 (n = 23), who underwent polymyxin hemoperfusion simultaneously with extended methods of extracorporeal hemocorrection, group 2 — children hospitalized in 2006—201 3 (n = 1 1), methods of extracorporeal hemocorrection were not performed. The Mann-Whitney U-test and ANOVA were used to evaluate the results.</p></sec><sec><title>Results and discussion</title><p>Results and discussion: the use of extracorporeal hemocorrection operations in the complex therapy of invasive forms of meningococcal infection with refractory septic shock and multiple organ failure syndrome in children provides stabilization of central hemodynamics, reduces clinical and laboratory inflammatory reactions, helps to reduce the dose of vasopressor drugs and parameters of respiratory support, and also increases patient survival rate by 82.6%.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>менингококковая инфекция</kwd><kwd>N. meningitidis</kwd><kwd>рефрактерный септический шок</kwd><kwd>синдром полиорганной недостаточности</kwd><kwd>экстракорпоральная терапия</kwd><kwd>полимиксиновая гемоперфузия</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>meningococcal infection</kwd><kwd>N. meningitidis</kwd><kwd>refractory septic shock</kwd><kwd>multiple organ failure syndrome</kwd><kwd>extracorporeal therapy</kwd><kwd>polymyxin hemoperfusion</kwd><kwd>children</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Скрипченко Н.В., Вильниц А.А. Менингококковая инфекция у детей. Санкт-Петербург: Тактик-Студио, 2015:840.</mixed-citation><mixed-citation xml:lang="en">Скрипченко Н.В., Вильниц А.А. Менингококковая инфекция у детей. Санкт-Петербург: Тактик-Студио, 2015:840.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2020: 299.</mixed-citation><mixed-citation xml:lang="en">[Skripchenko N.V, Vil'nits A.A. Meningococcal infection in children. St. Petersburg: Taktik-Studio,2015:840. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Brandtzaeg P., van Deuren M. Classification and pathogenesis of meningococcal infections. Methods Mol Biol. 2012; 799:21—35. doi: 10.1007/978-1-61779-346-2_2.</mixed-citation><mixed-citation xml:lang="en">On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019: State report. M.: Fed-eral'naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka=Federal Service for Surveillance on Consumer Rights Protection and Human Welfare. 2020:299. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rhodes A., Evans L.E., Alhazzani W, Levy M.M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar; 43(3):304— 377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.</mixed-citation><mixed-citation xml:lang="en">Brandtzaeg P., van Deuren M. Classification and pathogenesis of meningococcal infections. Methods Mol Biol. 2012; 799:21—35. doi: 10.1007/978-1-61779-346-2_2.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss S.L., Peters MJ., Alhazzani W, Agus M.S.D. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020 Feb; 46(Suppl 1): 10—67. doi: 10.1007/s00134-019-05878-6.</mixed-citation><mixed-citation xml:lang="en">Rhodes A., Evans L.E., Alhazzani W, Levy M.M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar; 43(3):304— 377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Белобородов В.Б. Нерешенные вопросы менингококковой инфекции. Инфекционные болезни. Новости. Мнения. Обучение. 2018; 1:46—53.</mixed-citation><mixed-citation xml:lang="en">Weiss S.L., Peters MJ., Alhazzani W, Agus M.S.D. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020 Feb; 46(Suppl 1): 10—67. doi: 10.1007/s001 34-019-05878-6.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Brusletto B.S., Hellerud B.C., Lоberg E.M., Goverud I.L., Vege A., Berg J.P., Brandtzaeg P., Оvstebо R. Traceability and distribution of Neisseria meningitidis DNA in archived post mortem tissue samples from patients with systemic meningococcal disease. BMC Clin Pathol. 2017 Aug 16; 17:10. doi: 10.1186/s12907-017-0049-9. eCollection 2017.</mixed-citation><mixed-citation xml:lang="en">Beloborodov V.B. Unresolved issues of meningococcal infection. Infektsionnye Bolezni. Novosti. Mneniya. Obuchenie=Infectious Diseases. News. Opinions. Training. 2018; 1:46—53 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Darton T., Guiver M., Naylor S., Jack D.L., Kaczmarski E.B., Borrow R., Read R.C.. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis. 2009 Mar 1; 48(5):587— 94. doi: 10.1086/596707.</mixed-citation><mixed-citation xml:lang="en">Brusletto B.S., Hellerud B.C., Lоberg E.M., Goverud I.L., Vege A., Berg J.P., Brandtzaeg P., Оvstebо R. Traceability and distribution of Neisseria meningitidis DNA in archived post mortem tissue samples from patients with systemic meningococcal disease. BMC Clin Pathol. 2017 Aug 16; 17:10. doi: 10.1186/s12907-017-0049-9. eCollection 2017.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hackett SJ., Guiver M., Marsh J., Sills J.A., Thomson A.P., Kaczmarski E.B., Hart C.A. Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child. 2002; 86(1):44— 6.</mixed-citation><mixed-citation xml:lang="en">Darton T., Guiver M., Naylor S., Jack D.L., Kaczmarski E.B., Borrow R., Read R.C.. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis. 2009 Mar 1; 48(5):587— 94. doi: 10.1086/596707.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ovstebo R., Brandtzaeg P., Brusletto B., Haug K.B., Lande K., Hoiby E.A., Kierulf P. Use of robotized DNA isolation and real-time pcr to quantify and identify close correlation between levels of neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol. 2004; 42(7):2980—7.</mixed-citation><mixed-citation xml:lang="en">Hackett SJ., Guiver M., Marsh J., Sills J.A., Thomson A.P., Kaczmarski E.B., Hart C.A. Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child. 2002; 86(1):44— 6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rosa S.D., Villa G., Ronco C. The golden hour of polymyxin B he-moperfusion in endotoxic shock: The basis for sequential extracorporeal therapy in sepsis. Artif Organs. 2020 Feb; 44(2):184—1 86. doi: 10.1111/aor.13550. Epub 2019 Sep 2.</mixed-citation><mixed-citation xml:lang="en">Ovstebo R., Brandtzaeg P., Brusletto B., Haug K.B., Lande K., Hoiby E.A., Kierulf P. Use of robotized DNA isolation and real-time pcr to quantify and identify close correlation between levels of neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol. 2004; 42(7):2980—7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Лобзин Ю.В., Иванова М.В., Скрипченко Н.В., Вильниц А.А., Карев В.Е., Горелик Е.Ю., Середняков К.В., Конев А.И. Современные клинико-эпидемиологические особенности течения генерализованной менингококковой инфекции и новые возможности терапии. Инфекционные болезни: новости, мнения, обучение. 2018; 7; 1(24):69—77.</mixed-citation><mixed-citation xml:lang="en">Rosa S.D., Villa G., Ronco C. The golden hour of polymyxin B he-moperfusion in endotoxic shock: The basis for sequential extracorporeal therapy in sepsis. Artif Organs. 2020 Feb; 44(2):184—1 86. doi: 10.1111/aor.13550. Epub 2019 Sep 2.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Carcillo Joseph A. Multiple Organ System Extracorporeal Support in Critically Ill Children. Pediatr Clin N Am. 2008; 55:617—646.</mixed-citation><mixed-citation xml:lang="en">Lobzin Yu.V., Ivanova M.V, Skripchenko N.V., Vil'nits A.A., Karev VE., Gorelik E.YU., Serednyakov K.V., Konev A.I. Modern clinical and epidemiological features of the course of generalized meningococcal infection and new treatment options. Infektsionnye Bolezni: novosti, mneniya, obuchenie=Infectious Diseases: News, Opinions, Education. 2018; 7; 1(24):69—77 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gomez-Jimenez J., Salgado A., Mourelle M., Martin M.C., Segura R.M., Peracaula R., Moncada S. L-arginin: nitric oxide pathway in endo-toxemia and human septic shock. Crit. Care Med. 1995; 23(2):253—258. doi: 10.1097/00003246-199502000-00009.</mixed-citation><mixed-citation xml:lang="en">Carcillo Joseph A. Multiple Organ System Extracorporeal Support in Critically Ill Children. Pediatr Clin N Am. 2008; 55:617—646.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Theilen U., Wilson L., Wilson G., Beattie J.O., Qureshi S, Simpson D. Management of invasive meningococcal disease in children and young people: summary of SIGN guidelines. BMJ. 2008; 336(7657): 1367—1370.</mixed-citation><mixed-citation xml:lang="en">Gomez-Jimenez J., Salgado A., Mourelle M., Martin M.C., Segura R.M., Peracaula R., Moncada S. L-arginin: nitric oxide pathway in endo-toxemia and human septic shock. Crit. Care Med. 1995; 23(2):253—258. doi: 10.1097/00003246-199502000-00009.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pelkonen T., Roine I., Cruzeiro M.L., Pitkaranta A., Kataja M., Pelto-la H. Slow initial P-lactam infusion and oral paracetamol to treat childhood bacterial meningitis:a randomised, controlled trial. The Lancet. Inf. Dis., 2011; 11 (8):613—621. doi: 10.1016/S1473-3099(11)70055-X</mixed-citation><mixed-citation xml:lang="en">Theilen U., Wilson L., Wilson G., Beattie J.O., Qureshi S, Simpson D. Management of invasive meningococcal disease in children and young people: summary of SIGN guidelines. BMJ. 2008; 336(7657): 1367—1370.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zagli G., Bonizzoli M., Spina R., Cianchi G., Pasquini A., Anichini V, Matano S., Tarantini F, Di Filippo A., Maggi E., Peris A. Efects of hemoperfusion with an immobilized polymyxin-B fber column on cytokine plasma levels in patients with abdominal sepsis. Minerva Anestesiol. 2010; (76):405—12.</mixed-citation><mixed-citation xml:lang="en">Pelkonen T., Roine I., Cruzeiro M.L., Pitkaranta A., Kataja M., Pelto-la H. Slow initial P-lactam infusion and oral paracetamol to treat childhood bacterial meningitis:a randomised, controlled trial. The Lancet. Inf. Dis., 2011; 11 (8):613—621. doi: 10.1016/S1473-3099(11)70055-X</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nishibori M., Takahashi H.K., Katayama H., Mori S., Saito S., Iwa-gaki H., Tanaka N., Morita K., Ohtsuka A. Specifc removal of monocytes from peripheral blood of septic patients by polymyxin B-immobilized flter column. Acta Med. Okayama. 2009; (63):65—9. PMID: 19247424. doi: 10.18926/AMO/31855.</mixed-citation><mixed-citation xml:lang="en">Zagli G., Bonizzoli M., Spina R., Cianchi G., Pasquini A., Anichini V, Matano S., Tarantini F, Di Filippo A., Maggi E., Peris A. Efects of hemoperfusion with an immobilized polymyxin-B fber column on cytokine plasma levels in patients with abdominal sepsis. Minerva Anestesiol. 2010; (76):405—12.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka Y., Okano K., Tsuchiya K., Yamamoto M., Nitta K.. Polymyxin B. Hemoperfusion improves hemodynamic status in patients with sepsis with both gram-negative and non-gram-negative bacteria. J. Clin. Exp. Nephrol., 2015; (1):4. DOI: 10.21767/2472—5056.100004</mixed-citation><mixed-citation xml:lang="en">Nishibori M., Takahashi H.K., Katayama H., Mori S., Saito S., Iwa-gaki H., Tanaka N., Morita K., Ohtsuka A. Specifc removal of monocytes from peripheral blood of septic patients by polymyxin B-immobilized flter column. Acta Med. Okayama. 2009; (63):65—9. PMID: 19247424. doi: 10.18926/AMO/31855.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Vatazin A.V, Zulkarnaev A.B., Krstich M. Effect of selective adsorption of endotoxin on mortality. Abstracts of the Scientific-Practical Conference «Actual Questions of Nephrology, Dialysis, Surgical Correction and Hemodialysis». Moscow, 2011:10.</mixed-citation><mixed-citation xml:lang="en">Tanaka Y., Okano K., Tsuchiya K., Yamamoto M., Nitta K.. Polymyxin B. Hemoperfusion improves hemodynamic status in patients with sepsis with both gram-negative and non-gram-negative bacteria. J. Clin. Exp. Nephrol., 2015; (1):4. DOI: 10.21767/2472—5056.100004</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ishibe Y., Shibata S., Takahashi G., Suzuki Y., Inoue Y., Endo S. Association of type II secretory phospholipase A2 and surfactant protein D with the pulmonary oxygenation potential in patients with septic shock during polymyxin-B immobilized fiber-direct hemoperfusion. J. Clin. Apher. Oct 2017; 32(5):302—10. DOI: 10.1002/jca.21507. PMID:27623356.</mixed-citation><mixed-citation xml:lang="en">Vatazin A.V, Zulkarnaev A.B., Krstich M. Effect of selective adsorption of endotoxin on mortality. Abstracts of the Scientific-Practical Conference «Actual Questions of Nephrology, Dialysis, Surgical Correction and Hemodialysis». Moscow, 2011:10.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Лобзин Ю.В., Скрипченко Н.В., Середняков К.В., Маркова К.В. Способ лечения генерализованной формы менингококковой инфекции у детей с рефрактерным септическим шоком и синдромом полиорганной недостаточности. Патент на изобретение RU 2712050 C1, 24.01.2020. Заявка № 2019123073 от 17.07.2019.</mixed-citation><mixed-citation xml:lang="en">Ishibe Y., Shibata S., Takahashi G., Suzuki Y., Inoue Y., Endo S. Association of type II secretory phospholipase A2 and surfactant protein D with the pulmonary oxygenation potential in patients with septic shock during polymyxin-B immobilized fiber-direct hemoperfusion. J. Clin. Apher. Oct 2017; 32(5):302—10. DOI: 10.1002/jca.21507. PMID:27623356.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Marshall J.C., Foster D., Vincent J.L., Cook DJ., Cohen J., Dellinger R.P., Opal S., Abraham E., Brett S.J., Smith T., Mehta S., Derzko A., Ro-maschin A., MEDIC study. Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. J Infect Dis. 2004; 190(3):527—34. doi: 10.1086/422254. Epub 2004 Jul 2.</mixed-citation><mixed-citation xml:lang="en">Lobzin Yu.V, Skripchenko N.V., Serednyakov K.V., Markova K.V Method of treating a generalized form of meningococcal infection in children with refractory septic shock and multiple organ failure syndrome. Patent na izobretenie=Patent for invention RU 2712050 C1, 24.01.2020. Application No. 2019123073 dated 17.07.2019 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Terayama T., Yamakawa K., Umemura Y., Aihara M., Fujimi S. Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Surg Infect (Larchmt). 2017; 18(3):225—233. doi: 10.1089/sur.2016.168. Epub 2017 Jan 16.</mixed-citation><mixed-citation xml:lang="en">Marshall J.C., Foster D., Vincent J.L., Cook DJ., Cohen J., Dellinger R.P., Opal S., Abraham E., Brett S.J., Smith T., Mehta S., Derzko A., Ro-maschin A., MEDIC study. Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. J Infect Dis. 2004; 190(3):527—34. doi: 10.1086/422254. Epub 2004 Jul 2.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Terayama T., Yamakawa K., Umemura Y., Aihara M., Fujimi S. Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Surg Infect (Larchmt). 2017; 18(3):225—233. doi: 10.1089/sur.2016.168. Epub 2017 Jan 16.</mixed-citation><mixed-citation xml:lang="en">Terayama T., Yamakawa K., Umemura Y., Aihara M., Fujimi S. Polymyxin B Hemoperfusion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Surg Infect (Larchmt). 2017; 18(3):225—233. doi: 10.1089/sur.2016.168. Epub 2017 Jan 16.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
